Here's Why Vaxcyte (PCVX) Sold Off in Q1
Carillon Tower Advisers, an investment management company, released its 'Carillon Eagle Small Cap Growth Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. Small-cap stocks experienced a significant drop in Q1, with the Russell 2000 Growth Index (down 11.12%) trailing the Russell 2000 Value Index (down 7.74%). In the Russell 2000 Growth Index, real estate, which increased by 1.76%, outperformed all sectors both absolutely and relatively. The only other sector delivering positive returns was consumer staples, which rose by 0.67%. In addition, please check the fund's top five holdings to know its best picks in 2025.
In its first-quarter 2025 investor letter, Carillon Eagle Small Cap Growth Fund highlighted stocks such as Vaxcyte, Inc. (NASDAQ:PCVX). Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology vaccine company that focuses on developing novel protein vaccines to prevent or treat bacterial infectious diseases. The one-month return of Vaxcyte, Inc. (NASDAQ:PCVX) was -1.09%, and its shares lost 52.68% of their value over the last 52 weeks. On May 23, 2025, Vaxcyte, Inc. (NASDAQ:PCVX) stock closed at $32.54 per share with a market capitalization of $4.198 billion.
Carillon Eagle Small Cap Growth Fund stated the following regarding Vaxcyte, Inc. (NASDAQ:PCVX) in its Q1 2025 investor letter:
"Vaxcyte, Inc. (NASDAQ:PCVX) is a leading biotechnology company focused on developing vaccines. The company is developing VAX24/VAX-31 for the prevention of pneumococcal disease in infants and adults. Phase 2 trial results for VAX-24 in infants were announced, demonstrating non-inferiority to another drug on nearly all serotypes tested. While the results were promising enough to proceed to phase 3, they were not as robust as previous VAX-24 trials. Additionally, the resignation of a key U.S. Food and Drug Administration leader, Dr. Peter Marks, shortly before the results were unveiled, raised concerns in the vaccine industry and contributed to a significant selloff in the stock. Despite these challenges, the company remains optimistic about the future of VAX-24 in phase 3 trials."
A research scientist in a laboratory holding a vial of a biotechnology drug.
Vaxcyte, Inc. (NASDAQ:PCVX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 45 hedge fund portfolios held Vaxcyte, Inc. (NASDAQ:PCVX) at the end of the first quarter, which was 50 in the previous quarter. While we acknowledge the potential of Vaxcyte, Inc. (NASDAQ:PCVX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.
In another article, we covered Vaxcyte, Inc. (NASDAQ:PCVX) and shared the list of stocks that will bounce back according to analysts. The fund stated in its Q4 2024 investor letter that Vaxcyte, Inc. (NASDAQ:PCVX) underperformed due to uncertainty surrounding its key vaccine candidates amid political shifts. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Salesforce, Inc. (CRM): A Bull Case Theory
We came across a bullish thesis on Salesforce, Inc. (CRM) on Compounding Your Wealth's Substack. In this article, we will summarize the bulls' thesis on CRM. Salesforce, Inc. (CRM)'s share was trading at $265.37 as of 30th May. CRM's trailing and forward P/E were 41.53 and 23.47 respectively according to Yahoo Finance. Pixabay/Public Domain Salesforce delivered solid Q1 FY2026 results, posting $9.83 billion in revenue, up 11% year-over-year, with subscription and support revenue growing 12% in constant currency. Remaining performance obligations (RPO) reached $60.9 billion, up 13%, reflecting strong demand visibility. Operating cash flow rose 4% to $6.5 billion. Salesforce reaffirmed its full-year guidance, including a 34% non-GAAP operating margin and 9–10% free cash flow growth. Sales Cloud drove 80% of large enterprise deals, with strength in verticals like financial services, healthcare, and retail. Account executive headcount is set to expand by 22% this year. Internationally, growth was robust in Canada, the UK, France, and South Asia, while Japan showed signs of acceleration. The company's AI initiatives are scaling rapidly—AgentForce, a generative AI product, now has over 4,000 paying customers and was featured in 800+ customer deployments, with potential to reach $1 billion in annualized revenue. Data Cloud surpassed $1 billion in ARR and is processing 22 trillion records, up 175% year-over-year. Tableau, MuleSoft, and Slack were also prominent in major deals, as customers increasingly adopt cross-cloud solutions. Salesforce highlighted Slack's evolution into an enterprise AI interface, improving lead routing times dramatically from 20 minutes to 19 seconds. The recent Informatica acquisition aims to enhance data harmonization and accelerate AI capabilities. Salesforce introduced Flex Credits, a usage-based pricing model reflecting early-stage but growing AI consumption. Notable customer wins included PepsiCo, OpenTable, and Takeda. The company raised its FY26 revenue outlook to $41.3 billion, underscoring its transformation toward data, AI, and unified platform-driven growth. Previously, we have covered Salesforce, Inc. (CRM) in April 2025 wherein we summarized a by Quality Equities on Substack. In the article, Salesforce (CRM) was highlighted as a structurally resilient, high-margin software business undervalued due to macroeconomic fears. The article argued that the market was underestimating Salesforce's long-term free cash flow growth, despite strong fundamentals, improving margins, and rising AI-driven innovation. Since our last coverage, the stock is up 13% as of 30th May. Salesforce, Inc. (CRM) is on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 140 hedge fund portfolios held CRM at the end of the first quarter which was 162 in the previous quarter. While we acknowledge the potential of CRM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Upstart Holdings, Inc. (UPST): A Bull Case Theory
We came across a bullish thesis on Upstart Holdings, Inc. (UPST) on Deep Value Retirns' Substack. In this article, we will summarize the bulls' thesis on UPST. Upstart Holdings, Inc. (UPST)'s share was trading at $47.17 as of 30th May. UPST's forward P/E was 28.90 according to Yahoo Finance. A data centre room with cloud technology, illustrating the enterprise application software services. Upstart (UPST) offers compelling upside potential if it can successfully navigate its current challenges and deliver on its growth ambitions. While the company is not yet producing clean free cash flow, management's target to achieve GAAP profitability by the second half of 2025 marks a significant step toward financial sustainability. Upstart's innovative platform and market position give it strong growth prospects, and if it can convert this growth into consistent free cash flow—targeting at least $25 million quarterly—it would validate the long-term investment thesis. Addressing the $700 million net debt and potential equity raise will be critical, but successful deleveraging would strengthen the balance sheet and reduce investor concerns. Achieving these milestones could lead to a substantial re-rating of the stock, with the current $100 per share price target representing a conservative estimate of its upside by mid-2026. For investors who believe in Upstart's technology and market opportunity, the company's path to profitability and improved cash flow generation offers an attractive risk/reward profile, positioning it well to capitalize on its growth potential and reward patient shareholders as it scales sustainably. Previously, we have covered Upstart Holdings, Inc. (UPST) in March 2025 wherein we summarized a by Unconventional Value on Substack. The author highlighted the company's AI-powered lending platform's improved risk models and strong 2024 growth, positioning the company for a recovery and continued expansion if economic conditions improve. Upstart Holdings, Inc. (UPST) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 33 hedge fund portfolios held UPST at the end of the first quarter which was 39 in the previous quarter. While we acknowledge the potential of UPST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
S&P 500 Gains and Losses Today: Lululemon Stock Falls as Forecasts Reflect Consumer Caution
The S&P 500 added 1% on Friday, June 6, as a strong jobs report pointed to resilience in the labor market despite tariff-related concerns. After retreating from record highs over the past few sessions, shares of data analytics firm Palantir bounced back, boosted by a signal of robust AI demand. Shares of Lululemon plummeted after the apparel maker cut its outlook for the current quarter and the full year, citing soft consumer U.S. equities indexes pushed higher to close out the trading week. The Bureau of Labor Statistics reported that the U.S. economy added 139,000 jobs in May, topping economists' forecasts and helping alleviate concerns about a tariff-driven slowdown in the labor market. The S&P 500 gained 1% on Friday, closing above the 6,000-point level for the first time since February. The Dow was up 1.1%, while the Nasdaq jumped 1.2%. Shares of big data analytics software provider Palantir Technologies (PLTR) popped 6.5% higher, securing the top daily performance in the S&P 500. Positivity around its expanding government business helped lift Palantir to an all-time high on Tuesday, but before Friday's gains, the stock had been pulling back for a couple of sessions. Palantir and other artificial intelligence companies benefited from upbeat sentiment after earnings results from chipmaker Broadcom (AVGO) revealed strong AI demand. Moderna (MRNA) shares wrapped up a volatile week of trading with a gain of 5.1% on Friday. The biotech company announced at the end of last week that it had received Food and Drug Administration (FDA) approval for the use of its new COVID-19 vaccine by older and higher-risk patients. On Tuesday, Health and Human Services Secretary Robert F. Kennedy Jr. said Moderna had agreed to a placebo-controlled trial of the vaccine. United Airlines (UAL) announced a partnership with Spotify Technology (SPOT) that will allow airborne passengers to access playlists, audiobooks, and video podcasts from the streaming service on their seatback screens. United shares increased 4.8% on Friday, while rival carrier Delta Air Lines (DAL) shares were up 4.3%. Tesla (TSLA) shares advanced 3.7% on Friday as the feud between Tesla CEO Elon Musk and U.S. President Donald Trump showed signs of de-escalation heading into the weekend. The spat between the two contributed to a major drop in the electric vehicle (EV) maker's stock in the prior session. Several analysts reaffirmed their bullishness on Tesla despite the high-profile conflict, but they noted that the tensions with Trump could complicate the regulatory path for the firm's self-driving technology or risk alienating people with certain political perspectives. Lululemon Athletica (LULU) issued lower-than-expected sales and profit guidance for the current quarter and trimmed its full-year profit forecast. The maker of yoga attire and other athletic apparel noted that U.S. consumers are taking a cautious approach to spending and discussed plans to increase prices on some products as it aims to mitigate tariff impacts. Lululemon shares plunged 19.8% on Friday, dropping the most of any constituent in the S&P 500. JPMorgan and UBS analysts cut their price targets on Lululemon stock following the underwhelming outlook. Broadcom posted fiscal second-quarter sales and adjusted profit results that were roughly in line with consensus forecasts. A major year-over-year uptick in artificial intelligence semiconductor revenue helped the chipmaker achieve record quarterly revenue of $15 billion. However, Broadcom shares slipped 5% on Friday, receding from a string of record highs notched before the earnings release. Mosaic (MOS), a provider of fertilizers and other agricultural products, reduced its 2025 phosphate production guidance, citing operational issues at its U.S. facilities. Shares of Mosaic were down 4.4%. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
